Phase 4 N=27 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
Postmenopausal Osteoporosis
Primary: Bone Turnover Marker (Blood Sample) — -7; 43 percentage of change in CTX
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=91 Comparison of Two Intermittent Urinary Catheters
Urinary Retention
Primary: Percentage of Participants — 91.5 percentage of participants
Phase 4 N=20 Absorption Comparison on Equivalency Value of Genepro Gen2
Analysis, Event History · Absorption; Disorder, Protein
Primary: Weekly Blood Draws to Measure Blood Protein Levels — 7.23; 6.86; 7.43; 7.21 grams per deciliter
Phase 2 N=54 A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer
Breast Cancer
Primary: The Number of Participants With a Significant Increase in Perfusion Defects (PD) — 1; 2; 3; 5 participants — p=0.6
Phase 2 N=40 Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection
Hepatitis C Virus Infection
Primary: Change From Baseline in Magnetic Resonance Spectroscopy (MRS) Metabolic Ratio at 4 Weeks After Discontinuation of Therapy: NAA + NAAG — -0.03; -0.01; -0.03; -0.09 ratio…
Phase 3 N=1,105 Apnea Positive Pressure Long-Term Efficacy Study
Lung Diseases · Sleep Apnea Syndromes · Sleep
Primary: Effect of CPAP on Neurocognitive Function: E/F Function- SWMT-OMD — 0.035; -0.074; 0.072; 0.018 score on a scale — p=0.0074
Phase 4 N=224 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
Hepatitis B · Tetanus · Poliomyelitis
Primary: Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP) — 92; 106 Subjects
Phase 1 N=25 Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Healthy
Primary: Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 6147; 6141 nanomol…
Phase 4 N=268 Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR
Anxiety Disorders
Primary: Hamilton Rating Scale for Anxiety — 4.17; 6.29; 11.35; 5.80 HAM-A Rating Score
Phase 3 N=125 A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.
Anemia
Primary: Mean Change in Hb Concentration g/dL Between Baseline and the Efficacy Evaluation Period — 1.75 g/dL
Phase 1 N=36 Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers
Healthy
Primary: Maximum Measured Concentration (Cmax) at Steady State for Telmisartan — 970; 857; 895 ng/mL
Phase 3 N=668 Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the FDA Snapshot Analysis — 94.3; 93.0 percentage of participants — p=0.5
Phase 4 N=37 Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist
ADHD · Stimulant-Induced Euphoria
Primary: Change in Score on AISRS From Baseline to Week 6 — -26.7; -29.1 units on a scale
N/A N=20 Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness
Acute Respiratory Failure
Primary: Improvement in VO2 — 16.9 ml/min
Phase 4 N=60 Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
Atrial Fibrillation
Primary: Pre-dose Concentration of the Analyte in Plasma at Steady State Immediately Before Administration of the Next Dose — 155 ng/mL